BRAINSTORM CELL THERAPEUTICS INC. Annual Report - How They Did This Year

I’ve put together this guide to help you understand BrainStorm Cell Therapeutics’ performance this past year. My goal is to turn complex financial filings into plain English so you can decide if this company fits your investment strategy.

1. What does this company do?

BrainStorm is a biotech firm developing "autologous" cell therapies, specifically their NurOwn® platform. They harvest a patient’s own bone marrow stem cells, treat them in a lab to boost their healing properties, and re-inject them to repair nerve tissue. They focus on neurodegenerative diseases like ALS and Progressive Multiple Sclerosis. Because they are still in the research phase, they generated $0 in sales for 2023 and reported a $26.8 million loss.

2. The Big News: The Regulatory Rollercoaster

The biggest story is the struggle to get NurOwn® approved for ALS. After an FDA advisory committee voted 17-1 against the treatment's effectiveness, the company withdrew its application in October 2023.

However, they are now working with the FDA on a new "Phase 3b" clinical trial. In early 2024, the FDA formally agreed to the trial's design. This is a major development because the FDA now agrees that if this trial hits its goals, the results could support a new approval application.

3. Financial Health and The "Delisting"

This is the most important section for you. BrainStorm is in "survival" mode. Since they have no product sales, they burn through $1.5 million to $2 million in cash every month to fund their research.

In July 2024, the company was delisted from the Nasdaq stock exchange. They failed to meet minimum requirements for shareholder equity. Their stock now trades on the "OTCQB Venture Market" under the ticker BCLI. This market is generally less prestigious and has lower trading volume, which can lead to higher price swings and make it harder to buy or sell shares quickly.

4. Key Risks for Investors

• More shares issued: To pay for the new trial, the company has been selling more shares and using debt. This reduces your ownership percentage in the company.
• Going Concern: The company’s auditors warned that BrainStorm may not have enough cash to operate for the next 12 months. They need to raise tens of millions of dollars to complete their upcoming trial.
• Legal Troubles: The company is defending against class-action lawsuits. Investors allege the company misled them about the success of the initial trial. These legal battles drain cash that could be used for research.

5. Future Outlook

The company’s future depends entirely on the success of the Phase 3b trial. They have the FDA’s approval on the plan, but they must still execute the study and find the money to pay for it. They are currently looking for partners to help cover these massive costs.

Bottom Line: This is a high-risk, "all-or-nothing" investment. You aren't buying a company with steady profits; you’re betting on the success of one medical trial. If the trial fails, the company may run out of money, which could lead to a total loss of your investment. Before moving forward, ask yourself if you are comfortable with the volatility of a company that is currently reliant on external funding and a single, high-stakes clinical outcome.